trending Market Intelligence /marketintelligence/en/news-insights/trending/juqzxoq1tjf9cnokon2kuw2 content esgSubNav
In This List

Zafgen names chief business officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Zafgen names chief business officer

Zafgen Inc. appointed Brian McVeigh as chief business officer, effective May 29.

Previously, McVeigh served as vice president of world wide business development, transactions and investment management at GlaxoSmithKline PLC in pharmaceuticals research and development from October 2011 until November 2017.

Boston, Mass.-based Zafgen is a clinical-stage biopharmaceutical company, which develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome, and other metabolically related disorders.